Irinotecan Hydrochloride Fluoroglucoside Liposome Injection(Nanjing Luye Pharma)

盐酸伊立替康氟脲苷脂质体注射液（南京绿叶制药）

Report date: 2025/08/28 17:05:46

Base Information

Drug NameIrinotecan Hydrochloride Fluoroglucoside Liposome Injection(Nanjing Luye Pharma)
Drug Alias NameIrinotecan hydrochloride-Floxuridine盐酸伊立替康和氟尿苷Irinotecan hydrochloride+Floxuridine盐酸伊立替康●氟尿苷Liposomal irinotecan/floxuridine +[22] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA topoisomerase I inhibitors
TargetsDNA topoisomerase I
Therapy Area/IndicationsSolid tumoursColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsYes
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesNanjing Luye Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNanjing Luye Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursColorectal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A